The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia Y Herishanu, P Pérez-Galán, D Liu, A Biancotto, S Pittaluga, B Vire, ... Blood, The Journal of the American Society of Hematology 117 (2), 563-574, 2011 | 1034 | 2011 |
The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status P Pérez-Galán, G Roué, N Villamor, E Montserrat, E Campo, D Colomer Blood 107 (1), 257-264, 2006 | 539 | 2006 |
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era P Pérez-Galán, M Dreyling, A Wiestner Blood, The Journal of the American Society of Hematology 117 (1), 26-38, 2011 | 479 | 2011 |
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells Q Wang, H Mora-Jensen, MA Weniger, P Perez-Galan, C Wolford, T Hai, ... Proceedings of the National Academy of Sciences 106 (7), 2200-2205, 2009 | 379 | 2009 |
The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak P Pérez-Galán, G Roué, N Villamor, E Campo, D Colomer Blood 109 (10), 4441-4449, 2007 | 241 | 2007 |
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma MC Vegliante, J Palomero, P Pérez-Galán, G Roué, G Castellano, ... Blood, The Journal of the American Society of Hematology 121 (12), 2175-2185, 2013 | 210 | 2013 |
Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Δψm loss, caspase-9 activity, and apoptosis in Jurkat cells S Gamen, A Anel, P Pérez-Galán, P Lasierra, D Johnson, A Piñeiro, ... Experimental cell research 258 (1), 223-235, 2000 | 174 | 2000 |
A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis J Pardo, P Pérez-Galán, S Gamen, I Marzo, I Monleón, AA Kaspar, ... The Journal of Immunology 167 (3), 1222-1229, 2001 | 147 | 2001 |
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 G Roué, P Pérez-Galán, A Mozos, M López-Guerra, S Xargay-Torrent, ... Blood, The Journal of the American Society of Hematology 117 (4), 1270-1279, 2011 | 127 | 2011 |
Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and-independent pathways acting on mitochondria I Marzo, P PÉREZ-GALÁN, P GIRALDO, D RUBIO-FÉLIX, A ANEL, ... Biochemical Journal 359 (3), 537-546, 2001 | 126 | 2001 |
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation P Pérez-Galán, H Mora-Jensen, MA Weniger, AL Shaffer III, EG Rizzatti, ... Blood, The Journal of the American Society of Hematology 117 (2), 542-552, 2011 | 123 | 2011 |
Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma A Moros, V Rodriguez, I Saborit-Villarroya, A Montraveta, P Balsas, ... Leukemia 28 (10), 2049-2059, 2014 | 115 | 2014 |
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma MA Weniger, EG Rizzatti, P Pérez-Galán, D Liu, Q Wang, PJ Munson, ... Clinical Cancer Research 17 (15), 5101-5112, 2011 | 105 | 2011 |
BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells P Perez-Galan, G Roue, M Lopez-Guerra, M Nguyen, N Villamor, ... Leukemia 22 (9), 1712-1720, 2008 | 104 | 2008 |
Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling G Roué, M López-Guerra, P Milpied, P Pérez-Galán, N Villamor, ... Clinical cancer research 14 (21), 6907-6915, 2008 | 102 | 2008 |
Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy SEM Herman, X Sun, EM McAuley, MM Hsieh, S Pittaluga, M Raffeld, ... Leukemia 27 (12), 2311-2321, 2013 | 100 | 2013 |
Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions M Castella, A Boronat, R Martín-Ibáñez, V Rodríguez, G Suñé, ... Molecular Therapy-Methods & Clinical Development 12, 134-144, 2019 | 95 | 2019 |
Selective inhibition of IκB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level G Roué, P Pérez-Galán, M López-Guerra, N Villamor, E Campo, ... The Journal of Immunology 178 (3), 1923-1930, 2007 | 95 | 2007 |
Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives I Salaverria, P Perez-Galan, D Colomer, E Campo Haematologica 91 (1), 11-16, 2006 | 95 | 2006 |
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, JG Valero, A Chamorro-Jorganes, D Gonzalez, ... Oncogene 37 (14), 1830-1844, 2018 | 87 | 2018 |